Literature DB >> 8912548

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.

G J Rustin1, T G Quinnell, J Johnson, H Clarke, A E Nelstrop, W Bollag.   

Abstract

Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8912548      PMCID： PMC2074772          DOI： 10.1038/bjc.1996.568

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  11 in total

1.  The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer.

Authors:  M E van der Burg; F B Lammes; J Verweij
Journal:  Ann Oncol       Date:  1990-07       Impact factor: 32.976

2.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

Authors:  G J Rustin; A E Nelstrop; P McClean; M F Brady; W P McGuire; W J Hoskins; H Mitchell; H E Lambert
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

3.  Topical calcipotriol treatment in advanced breast cancer.

Authors:  M Bower; K W Colston; R C Stein; A Hedley; J C Gazet; H T Ford; R C Combes
Journal:  Lancet       Date:  1991-03-23       Impact factor: 79.321

4.  Cutaneous T-cell lymphoma and calcitriol and isotretinoin treatment.

Authors:  K Thomsen
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

5.  Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin.

Authors:  L E French; A A Ramelet; J H Saurat
Journal:  Lancet       Date:  1994-09-03       Impact factor: 79.321

6.  Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions.

Authors:  S Majewski; M Skopinska; W Bollag; S Jablonska
Journal:  Lancet       Date:  1994-11-26       Impact factor: 79.321

Review 7.  Retinoids in cancer therapy.

Authors:  M A Smith; D R Parkinson; B D Cheson; M A Friedman
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

8.  Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.

Authors:  G J Rustin; A E Nelstrop; M K Tuxen; H E Lambert
Journal:  Ann Oncol       Date:  1996-04       Impact factor: 32.976

9.  13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.

Authors:  S M Lippman; J J Kavanagh; M Paredes-Espinoza; F Delgadillo-Madrueño; P Paredes-Casillas; W K Hong; E Holdener; I H Krakoff
Journal:  J Natl Cancer Inst       Date:  1992-02-19       Impact factor: 13.506

10.  Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.

Authors:  V Raina; D Cunningham; N Gilchrist; M Soukop
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640
View more
  1 in total

1.  The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.

Authors:  Jenny M Whitworth; Angelina I Londoño-Joshi; Jeffrey C Sellers; Patsy J Oliver; Donald D Muccio; Venkatram R Atigadda; J Michael Straughn; Donald J Buchsbaum
Journal:  Gynecol Oncol       Date:  2011-12-09       Impact factor: 5.482
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.